Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282033105> ?p ?o ?g. }
- W4282033105 endingPage "505" @default.
- W4282033105 startingPage "495" @default.
- W4282033105 abstract "Teclistamab is a T-cell-redirecting bispecific antibody that targets both CD3 expressed on the surface of T cells and B-cell maturation antigen expressed on the surface of myeloma cells. In the phase 1 dose-defining portion of the study, teclistamab showed promising efficacy in patients with relapsed or refractory multiple myeloma.In this phase 1-2 study, we enrolled patients who had relapsed or refractory myeloma after at least three therapy lines, including triple-class exposure to an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody. Patients received a weekly subcutaneous injection of teclistamab (at a dose of 1.5 mg per kilogram of body weight) after receiving step-up doses of 0.06 mg and 0.3 mg per kilogram. The primary end point was the overall response (partial response or better).Among 165 patients who received teclistamab, 77.6% had triple-class refractory disease (median, five previous therapy lines). With a median follow-up of 14.1 months, the overall response rate was 63.0%, with 65 patients (39.4%) having a complete response or better. A total of 44 patients (26.7%) were found to have no minimal residual disease (MRD); the MRD-negativity rate among the patients with a complete response or better was 46%. The median duration of response was 18.4 months (95% confidence interval [CI], 14.9 to not estimable). The median duration of progression-free survival was 11.3 months (95% CI, 8.8 to 17.1). Common adverse events included cytokine release syndrome (in 72.1% of the patients; grade 3, 0.6%; no grade 4), neutropenia (in 70.9%; grade 3 or 4, 64.2%), anemia (in 52.1%; grade 3 or 4, 37.0%), and thrombocytopenia (in 40.0%; grade 3 or 4, 21.2%). Infections were frequent (in 76.4%; grade 3 or 4, 44.8%). Neurotoxic events occurred in 24 patients (14.5%), including immune effector cell-associated neurotoxicity syndrome in 5 patients (3.0%; all grade 1 or 2).Teclistamab resulted in a high rate of deep and durable response in patients with triple-class-exposed relapsed or refractory multiple myeloma. Cytopenias and infections were common; toxic effects that were consistent with T-cell redirection were mostly grade 1 or 2. (Funded by Janssen Research and Development; MajesTEC-1 ClinicalTrials.gov numbers, NCT03145181 and NCT04557098.)." @default.
- W4282033105 created "2022-06-13" @default.
- W4282033105 creator A5006108161 @default.
- W4282033105 creator A5006799794 @default.
- W4282033105 creator A5009378735 @default.
- W4282033105 creator A5011811956 @default.
- W4282033105 creator A5014436946 @default.
- W4282033105 creator A5015647468 @default.
- W4282033105 creator A5015898454 @default.
- W4282033105 creator A5017390274 @default.
- W4282033105 creator A5022520524 @default.
- W4282033105 creator A5027117655 @default.
- W4282033105 creator A5027311948 @default.
- W4282033105 creator A5029159537 @default.
- W4282033105 creator A5032546995 @default.
- W4282033105 creator A5035811221 @default.
- W4282033105 creator A5035985145 @default.
- W4282033105 creator A5039555935 @default.
- W4282033105 creator A5048661030 @default.
- W4282033105 creator A5048953580 @default.
- W4282033105 creator A5054952877 @default.
- W4282033105 creator A5055684106 @default.
- W4282033105 creator A5056008039 @default.
- W4282033105 creator A5057090502 @default.
- W4282033105 creator A5059086219 @default.
- W4282033105 creator A5065238694 @default.
- W4282033105 creator A5066234242 @default.
- W4282033105 creator A5067790229 @default.
- W4282033105 creator A5069449708 @default.
- W4282033105 creator A5069748830 @default.
- W4282033105 creator A5070014603 @default.
- W4282033105 creator A5072062495 @default.
- W4282033105 creator A5072212184 @default.
- W4282033105 creator A5082564837 @default.
- W4282033105 creator A5089163384 @default.
- W4282033105 creator A5089275540 @default.
- W4282033105 date "2022-08-11" @default.
- W4282033105 modified "2023-10-18" @default.
- W4282033105 title "Teclistamab in Relapsed or Refractory Multiple Myeloma" @default.
- W4282033105 cites W1978643311 @default.
- W4282033105 cites W2003734726 @default.
- W4282033105 cites W2127132803 @default.
- W4282033105 cites W2460376887 @default.
- W4282033105 cites W2486629951 @default.
- W4282033105 cites W2905654445 @default.
- W4282033105 cites W2954506039 @default.
- W4282033105 cites W2995934717 @default.
- W4282033105 cites W3006655689 @default.
- W4282033105 cites W3087111554 @default.
- W4282033105 cites W3097738396 @default.
- W4282033105 cites W3111394247 @default.
- W4282033105 cites W3112088296 @default.
- W4282033105 cites W3133229959 @default.
- W4282033105 cites W3138534794 @default.
- W4282033105 cites W3166305669 @default.
- W4282033105 cites W3176532045 @default.
- W4282033105 cites W3180549397 @default.
- W4282033105 cites W3188071931 @default.
- W4282033105 cites W3198713553 @default.
- W4282033105 cites W3213622034 @default.
- W4282033105 cites W4221027512 @default.
- W4282033105 cites W4286298030 @default.
- W4282033105 doi "https://doi.org/10.1056/nejmoa2203478" @default.
- W4282033105 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35661166" @default.
- W4282033105 hasPublicationYear "2022" @default.
- W4282033105 type Work @default.
- W4282033105 citedByCount "177" @default.
- W4282033105 countsByYear W42820331052022 @default.
- W4282033105 countsByYear W42820331052023 @default.
- W4282033105 crossrefType "journal-article" @default.
- W4282033105 hasAuthorship W4282033105A5006108161 @default.
- W4282033105 hasAuthorship W4282033105A5006799794 @default.
- W4282033105 hasAuthorship W4282033105A5009378735 @default.
- W4282033105 hasAuthorship W4282033105A5011811956 @default.
- W4282033105 hasAuthorship W4282033105A5014436946 @default.
- W4282033105 hasAuthorship W4282033105A5015647468 @default.
- W4282033105 hasAuthorship W4282033105A5015898454 @default.
- W4282033105 hasAuthorship W4282033105A5017390274 @default.
- W4282033105 hasAuthorship W4282033105A5022520524 @default.
- W4282033105 hasAuthorship W4282033105A5027117655 @default.
- W4282033105 hasAuthorship W4282033105A5027311948 @default.
- W4282033105 hasAuthorship W4282033105A5029159537 @default.
- W4282033105 hasAuthorship W4282033105A5032546995 @default.
- W4282033105 hasAuthorship W4282033105A5035811221 @default.
- W4282033105 hasAuthorship W4282033105A5035985145 @default.
- W4282033105 hasAuthorship W4282033105A5039555935 @default.
- W4282033105 hasAuthorship W4282033105A5048661030 @default.
- W4282033105 hasAuthorship W4282033105A5048953580 @default.
- W4282033105 hasAuthorship W4282033105A5054952877 @default.
- W4282033105 hasAuthorship W4282033105A5055684106 @default.
- W4282033105 hasAuthorship W4282033105A5056008039 @default.
- W4282033105 hasAuthorship W4282033105A5057090502 @default.
- W4282033105 hasAuthorship W4282033105A5059086219 @default.
- W4282033105 hasAuthorship W4282033105A5065238694 @default.
- W4282033105 hasAuthorship W4282033105A5066234242 @default.
- W4282033105 hasAuthorship W4282033105A5067790229 @default.
- W4282033105 hasAuthorship W4282033105A5069449708 @default.
- W4282033105 hasAuthorship W4282033105A5069748830 @default.